TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).
The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.
Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。